Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:53:57 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:RGNX from 2023-04-27 to 2024-04-26 - 42 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 07:05U:RGNXNews ReleaseREGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
2024-03-28 07:05U:RGNXNews ReleaseREGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
2024-03-27 16:05U:RGNXNews ReleaseREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
2024-03-11 07:05U:RGNXNews ReleaseREGENXBIO to Participate in Upcoming Investor Conferences
2024-03-06 23:20U:RGNXNews ReleaseREGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
2024-03-06 16:10U:RGNXNews ReleaseREGENXBIO Announces Proposed Public Offering of Common Stock
2024-03-05 07:05U:RGNXNews ReleaseREGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE(TM) TRIAL
2024-02-29 16:57U:RGNXNews ReleaseREGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE(TM) Trial
2024-02-27 16:05U:RGNXNews ReleaseREGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2024-02-21 07:05U:RGNXNews ReleaseREGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2024-02-07 11:40U:RGNXNews ReleaseREGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
2024-02-07 07:05U:RGNXNews ReleaseREGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE ‚ ® Trial
2024-01-31 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
2024-01-16 14:47U:RGNXNews ReleaseREGENXBIO Announces Positive Interim Data from Phase II AAVIATE ‚ ® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
2024-01-10 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
2024-01-08 07:05U:RGNXNews ReleaseU.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV ‚ ® Technology Patent Infringement Lawsuit
2023-11-29 07:05U:RGNXNews ReleaseREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE ‚ ® Trial
2023-11-08 16:05U:RGNXNews ReleaseREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
2023-11-07 07:05U:RGNXNews ReleaseREGENXBIO to Participate in Upcoming Investor Conferences
2023-11-03 18:53U:RGNXNews ReleaseREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE ‚ ® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
2023-11-01 07:05U:RGNXNews ReleaseREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
2023-10-30 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
2023-10-05 07:05U:RGNXNews ReleaseREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
2023-10-03 16:05U:RGNXNews ReleaseREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE ¢ „ ¢ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
2023-09-26 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society
2023-09-05 07:05U:RGNXNews ReleaseREGENXBIO to Participate in Upcoming Investor Conferences
2023-08-30 07:05U:RGNXNews ReleaseInitial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium
2023-08-23 16:05U:RGNXNews ReleaseREGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
2023-08-02 16:05U:RGNXNews ReleaseREGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
2023-08-01 16:05U:RGNXNews ReleaseREGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
2023-07-26 07:05U:RGNXNews ReleaseREGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
2023-07-24 16:05U:RGNXNews ReleaseREGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
2023-07-11 07:05U:RGNXNews ReleaseREGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
2023-06-27 07:05U:RGNXNews ReleaseREGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
2023-06-20 08:00U:RGNXNews ReleaseREGENXBIO and University of Pennsylvania File NAV ‚ ® Technology Patent Infringement Lawsuit
2023-06-01 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
2023-05-23 07:05U:RGNXNews ReleaseREGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
2023-05-22 07:05U:RGNXNews ReleaseREGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023
2023-05-16 17:52U:RGNXNews ReleaseREGENXBIO Announces NAV ‚ ® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
2023-05-08 07:05U:RGNXNews ReleaseREGENXBIO to Participate in Upcoming Investor Conferences
2023-05-03 16:05U:RGNXNews ReleaseREGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
2023-05-02 16:53U:RGNXNews ReleaseREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting